




Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor

St.Peter DM, Steger JS, Patnaik JL, Davis N, Kahook MY, Seibold LK
doi: 10.2147/MDER.S397654. Published 2023.




Nanodropper extends bottle-life by 2.6x



Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children

Hoppe CB, Yonamine S, Kao BW, Turner ML, Ou Y, Han Y, Keenan JD, Oatts JT
doi: 10.1016/j.opth.2022.10.016. Published 2023. Clinicaltrials.gov: NCT05274321




In pediatric eyes:
Non-inferiority of mydriatic microdrops established for maximum pupil diameter



The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter

Chow A, Choi J, Bacharach J
doi: 10.2147/OPHTH.S504416. Published 2025. Clinicaltrials.gov: NCT06689904



In adult eyes:
Non-inferiority of mydriatic microdrops established for mean pupil diameter





An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Steger JS, Durai I, Odayappan A, Raman R, Sruthi T, Song AJ, Puthuran G, Venkatesh R, Colantuoni E, Robin AL

doi: 10.2147/OPHTH.S504416. Published 2024.

Clinicaltrials.gov: NCT06689904



No between-group difference in IOP at any time point Microdrops reduced heart rate significantly less than conventional drops




Twelve-Week Randomized, Controlled, Non-Inferiority Trial Evaluating the Safety and Efficacy of IOP-Lowering Microdrops Administered with the Nanodropper® Adaptor in Glaucoma Patients

Steger JS, Capó-Aponte JE, Papp A, Schulte AJ, Song AJ, Colantuoni E, Kelstrom JC

doi: DOI: 10.1097/j.jcrs.0000000000001823. Published 2026.

Clinicaltrials.gov: NCT05844384



n = 30 in conventional drop group, 29 in microdrops group; Error bars: Mean ± SEM; * p<0.05.

At 12 weeks, in stable glaucoma patients:

- Non-inferiority and superiority of microdrops established
- Microdrops decreased IOP from baseline by 1.6 mm Hg
- Microdrops decreased EBE prevalence by 80% and AE prevalence by 67%



← Download a PDF copy or access full publications at: nanodropper.com/pubs

Learn more: nanodropper.com
Connect: pro@nanodropper.com